Idelalisib
Back to searchMolecule Structure
Scientific Name
Idelalisib
Description of the Drug
Idelalisib is an antineoplastic kinase inhibitor used to treat chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL).
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB09054
http://www.drugbank.ca/drugs/DB09054
Brand Name(s)
Zydelig
Company Owner(s)
Gilead Sciences Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
PI3-kinase p110-delta subunit | SINGLE PROTEIN | INHIBITOR | CHEMBL3130 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL356400 | SCHEMBL16782604 | |
DrugBank | DB09054 | ||
PubChem: Thomson Pharma | 16728852 | ||
PubChem | 11625818 | ||
LINCS | LSM-1205 | ||
Nikkaji | J3.231.674C | ||
PDBe | 40L | ||
BindingDB | 150175 | 50403068 | |
DrugCentral | 4878 | ||
Brenda | 213179 | 213206 | 19712 |
ChemicalBook | CB32538915 | CB62638450 | |
Guide to Pharmacology | 6741 | ||
rxnorm | IDELALISIB | ZYDELIG | |
PubChem: Drugs of the Future | 136350004 | ||
ChEBI | 82701 | ||
ZINC | ZINC000013986658 |